Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
![]() |
V29112 | MARK Substrate | 847991-34-8 | MARK Substrate is a MARK substrate. |
![]() |
V29252 | Mast Cell Degranulating Peptide HR-2 | 80388-04-1 | Mast Cell Degranulating Peptide HR-2 is a 14-membered linear peptide extracted from the venom of the Eastern bumble bee that degranulates mast cells, thereby triggering histamine release. |
![]() |
V25067 | Masticadienediol | 6138-94-9 | Masticadienediol is a novel and potent tetracyclic triterpene |
![]() |
V29575 | Masupirdine free base | 701205-60-9 | Masupirdine free base (SUVN-502 free base) is a potent, selective, orally bioavailable and brain barrier-penetrating 5-HT6 receptor blocker (antagonist) (Ki for human 5-HT6 receptor is 2.04 nM). |
![]() |
V25063 | MAT2A inhibitor | 2201057-10-3 | MAT2A inhibitor is a novel and potent methionine adenosyltransferase 2A (MATA2) inhibitor (IC50< l00 nM). |
![]() |
V25068 | Matlystatin A | 140626-94-4 | Matlystatin A is a novel and potent aminopeptidase inhibitor with activity against aminopeptidase N and matrix metalloproteinases (MMP). |
![]() |
V25072 | Mavelertinib (PF06747775) | 1776112-90-3 | Mavelertinib (formerly PF-06747775; PF06747775) is amutant-selective,orally bioactive and irreversible/covalent inhibitor of the epidermal growth factor receptor (EGFR) T790M. |
![]() |
V13786 | Mavoglurant | 543906-09-8 | Mavoglurant (AFQ-056; AFQ056) is a potent and non-competitive mGlu5 (metabotropic glutamate receptor 5) receptor antagonist (IC50=30 nM) with the potential to be used for treatment of fragile X syndrome. |
![]() |
V41315 | MAX-10181 HCl | MAX-10181 is a novel, potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor, currently under phase 1 clinical trial. | |
![]() |
V25082 | MB 05032 | 261365-11-1 | MB 05032 is a novel and potent FBPase inhibitor |
![]() |
V11469 | MB-07133 | 685111-92-6 | MB-07133 is a novel and potent cytarabine (araC) prodrug |
![]() |
V28949 | MB-07729 | 882755-95-5 | MB-07729 is a novel and potent fructose 1,6-bisphosphatase (FBPase) inhibitor |
![]() |
V25086 | MB-07803 | 882757-24-6 | MB-07803 is a novel and potent FBPase inhibitor |
![]() |
V25087 | MB-11362 | 1159183-97-7 | MB-11362 is a novel and potent HCV nonstructural protein 5B (NS5B) inhibitor |
![]() |
V25088 | MB-28767 | 80558-61-8 | MB-28767 is a novel and potent prostaglandin E2 (PGE2) receptor agonist |
![]() |
V21018 | MB21 | 1870007-38-7 | MB21 is a novel and potent inhibitor of dengue type 2 protease |
![]() |
V25089 | MB710 | 2230044-57-0 | MB710 is an aminobenzothiazole analogue and a stabilizer of the oncogenic p53 mutant Y220C. |
![]() |
V25090 | MB725 | 2230058-99-6 | MB725 is a novel and potent inducer of viability reduction |
![]() |
V25091 | MBA | 116234-45-8 | MBA is a novel and potent bioactive molecule |
![]() |
V25092 | MBC-11 | 332863-86-2 | MBC-11 is a first-of-its-kind, bone-targeting conjugate of ethyl bisphosphonate covalently bound to the antimetabolite cytarabine (araC). |